Case report: Complete response in TMB-H advanced uterine clear cell carcinoma: a case analysis of paclitaxel albumin-bound combined with PD-1/CTLA-4 bispecific antibody
This case illustrates how effective AK104/Cadonilimab (a PD-1/CTLA-4 bispecific) can be when combined with albumin-bound paclitaxel for treating advanced UCCC, especially in patients who have not responded to standard therapies. The patient's complete and lasting response shows the potential of PD-1/CTLA-4 bispecific immunotherapy. This suggests that cadonilimab could provide important clinical benefits for patients with advanced or recurrent UCCC.
Authors
- Wenting Zhou (ORCID: https://orcid.org/0000-0002-4360-1231)
- Yue Chen (ORCID: https://orcid.org/0000-0001-7325-1845)
- Yili Wang (ORCID: https://orcid.org/0000-0002-8772-0005)
Institutions
- First Affiliated Hospital of Gannan Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.3389/fimmu.2024.1486200
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.54